<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276155</url>
  </required_header>
  <id_info>
    <org_study_id>CHPAU2020/01</org_study_id>
    <nct_id>NCT04276155</nct_id>
  </id_info>
  <brief_title>Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia</brief_title>
  <acronym>SCA FA</acronym>
  <official_title>Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia: A Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de PAU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier de PAU</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Acute Coronary Syndrome associated with de novo atrial fibrillation are&#xD;
      randomized to benefit from either a conventional therapy associating dual antiplatelet&#xD;
      therapy (DAPT) and anticoagulant or DAPT and an implantable monitoring device with a&#xD;
      follow-up by telecardiology&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Coronary Syndrome associated with de novo atrial fibrillation is not uncommon. It&#xD;
      worsens the short-term, medium-term and long-term prognosis. It is then usual, according to&#xD;
      ESC recommendations, to add to the DAPT, an anticoagulant treatment, which is a source of&#xD;
      iatrogenic events, in particular hemorrhagic events. However, recurrence is not a certainty.&#xD;
      Albeit variable, its highest rate is estimated to be 38%. Consequently, a well-conducted&#xD;
      screening of atrial fibrillation recurrence could allow to treat only selected recurrent&#xD;
      patients. At present, this screening can be carried out in a reliable and minimally invasive&#xD;
      way with an implantable device with telecardiology. We propose a study for these patients&#xD;
      with ACS associated with de novo AF. The study will be multicenter, randomized, open-label,&#xD;
      with two arms: patient conventionally treated (DAPT + AC) and patient treated by DAPT +&#xD;
      implantable device and followed for two years by telecardiology. This patient will only&#xD;
      reintegrate the first arm in case of AF recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective trial of therapeutic strategy, interventional, randomized and open-label, national and multicenter</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of hemorrhagic events</measure>
    <time_frame>2 years</time_frame>
    <description>To show that the introduction of an anticoagulant treatment in patients with ACS and de novo AF based on the data furnished by an implantable holter with remote monitoring is safer in terms of occurrence of hemorrhagic events than the systematic introduction of an anticoagulant treatment associated to DAPT based on the CHA2DS2-VASc score.&#xD;
CHA2DS2-Vasc score, derived from CHADS2 score. It assesses the risk of a person with atrial fibrillation (AF) without associated valve pathology, to experience an ischemic stroke, in other words, to assess the need for anticoagulant treatment. It ranges from 0 to 10. A score of 0 is considered a low risk. A score greater than or equal to 2 is considered a significant risk of embolic complication and should lead to discussion of the introduction of oral anticoagulant therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atrial Fibrillation, Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute Coranary Syndrome and de novo Atrial Fibrilation patients treated by DAPT only, in association with an implantable cardiac monitoring device and a follow-up by telecardiology. The anticoagulant treatment will only be administered to patients presenting a recurrence of Atrial Fibrilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Acute Coranary Syndrome and de novo Atrial Fibrilation patients with standard management: DAPT in association with an anticoagulant treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-systematic prescription of anticoagulant therapy</intervention_name>
    <description>the prescription of anticoagulant is managed by an implantable device follow up</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation diagnosed before hospitalization for acute coronary syndrome,&#xD;
             whether treated or not.&#xD;
&#xD;
          -  Atrial fibrillation still present at inclusion time.&#xD;
&#xD;
          -  Transient atrial fibrillation due to a reversible disorder (thyrotoxycosis, pulmonary&#xD;
             embolism, recent surgery).&#xD;
&#xD;
          -  Acute coronary syndrome that has not been revascularized.&#xD;
&#xD;
          -  Acute coronary syndrome surgically treated (bypass).&#xD;
&#xD;
          -  Patient already on anticoagulant therapy.&#xD;
&#xD;
          -  Scheduled aortocoronary bypass.&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml per minute.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pathologic criteria :&#xD;
&#xD;
          -  Atrial fibrillation diagnosed before hospitalization for acute coronary syndrome,&#xD;
             whether treated or not.&#xD;
&#xD;
          -  Atrial fibrillation still present at inclusion time.&#xD;
&#xD;
          -  Transient atrial fibrillation due to a reversible disorder (thyrotoxycosis, pulmonary&#xD;
             embolism, recent surgery).&#xD;
&#xD;
          -  Acute coronary syndrome that has not been revascularized.&#xD;
&#xD;
          -  Acute coronary syndrome surgically treated (bypass).&#xD;
&#xD;
          -  Patient already on anticoagulant therapy.&#xD;
&#xD;
          -  Scheduled aortocoronary bypass.&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml per minute.&#xD;
&#xD;
        Bleeding risks :&#xD;
&#xD;
          -  Contraindications to anticoagulant therapy.&#xD;
&#xD;
          -  Active internal hemorrhage, clinically significant bleeding, bleeding non accessible&#xD;
             to compression or bleeding diathesis within 30 days prior to selection visit.&#xD;
&#xD;
          -  Platelet count &lt; 90000/µL at the selection visit.&#xD;
&#xD;
          -  Bleeding event in the twelve months prior to inclusion.&#xD;
&#xD;
          -  Bleeding events detected either clinically or biologically (hemoglobinemia &lt; 10g/dl).&#xD;
&#xD;
          -  Elective surgery.&#xD;
&#xD;
        Comorbidities :&#xD;
&#xD;
          -  Cardiogenic shock.&#xD;
&#xD;
          -  Hyperthyroidism.&#xD;
&#xD;
          -  Prior history of significant liver disease (acute hepatitis, active chronic hepatitis,&#xD;
             cirrhosis) or liver function disorder detected at selection visit.&#xD;
&#xD;
          -  Significant mitral valvular heart disease.&#xD;
&#xD;
        General :&#xD;
&#xD;
          -  Patient under 18.&#xD;
&#xD;
          -  Non menopausal woman or without contraception.&#xD;
&#xD;
          -  Patient whose physical and / or mental health may have an impact on the compliance to&#xD;
             the study.&#xD;
&#xD;
          -  Participation in another biomedical research study (interventional or&#xD;
             noninterventional) or participation in a research study within the 30 days prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  Protected adults (under judicial protection, guardianship, or supervision).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alice Séris</last_name>
    <phone>05 59 72 69 97</phone>
    <email>alice.seris@ch-pau.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier d'Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard JOUVE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Chartres Louis Pasteur le Coudray</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck ALBERT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Haguenau</name>
      <address>
        <city>Haguenau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien DEPOLI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine MILHEM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Libournes</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre CHEVALLEREAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Annecy Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine DOMPNIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Centre h de Pau</last_name>
      <phone>0559726997</phone>
      <email>serisa01@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas DELARCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Périgueux</name>
      <address>
        <city>Périgueux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean LITALIEN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndromes, Atrial Fibrillation, Anticoagulant therapy, Implantable device, Telecardiology.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

